Decentralized Clinical Trials Market is set to witness a CAGR of 10% to reach $14.2 billion by 2026

Growing adoption by pharmaceutical, medical device companies & CROs, formation of industry stakeholder groups, favorable funding & regulatory outlook and surge in M&A activities are the key factors driving decentralized clinical trials market growth.
 
BRUSSELS - June 27, 2022 - PRLog -- Decentralized clinical trials (DCTs) employ a method of conducting clinical trials where parts or all of the trial happen outside a traditional physical clinic or trial site. Clinical trial studies are conducted via telemedicine, mobile/local healthcare providers & digital/mobile technologies.

Covid-19 fuels the Adoption of Decentralized Clinical Trials Market

Covid-19 pandemic has adversely impacted all the health services worldwide and the clinical industry was no exception. More than 2000 trials registered on ClinicalTrials.gov were terminated because of the challenges of doing clinical research during the Covid-19 pandemic. Covid-19 adversely impacted participant recruitment, retention, the safety of trial subjects, protocol compliance, and highlighted the need for safe, reliable, and secure remote capabilities, which in turn led to a renewed focus on digitization.

In the wake of the Covid-19 pandemic, decentralized clinical trials (DCT) emerged as an important tool using which patients can be recruited remotely, physician visits/patient consent can take place via telemedicine, and mobile technology can be used for remote data collection.

Regulatory Hurdles Likely to Hamper the Decentralized Clinical Trials Market

Clinical trial regulations have not kept pace with the digital tools and technologies used for decentralized trials. For instance, for healthcare wearable devices, there is an essential need to create an ecosystem where data from various devices and technologies are standardized, validated, and exchanged without data integrity issues.

Regulatory agencies follow multiple approaches to DCTs, but currently, there is no international standard. The DCT regulatory landscape is changing rapidly, and hence clinical-trial sponsors need to align their studies with the most up-to-date and latest guidelines. For multi-regional clinical trials, there is a need to recognize the increased regulations and limited possibilities for variation in research methods. A customized strategy and consideration for complexity in the clinical trial design are required for all global clinical trials that implement decentralization.

The decentralized clinical trials market is a booming market which is expected to gain further momentum in the upcoming years due to its ability to harness technological developments to improve the efficiency, participant experience, and generalizability of clinical studies.

Competitive Landscape Analysis: Decentralized Clinical Trials Market

The decentralized clinical trials market is marked by the presence of top market players such as ICON, Parexel, IQVIA, Covance, Thermo Fisher, LEO Innovation Lab, Huma, Medidata (part of Dassault), Oracle, CRF Health, Medable, Signant Health, and Clinical Ink, among others.

Get Customized Research Report on Decentralized Clinical Trials Market @ https://meditechinsights.com/decentralized-clinical-trials-market/

Contact
Medi-Tech Insights
aves.s@meditechinsights.com
32 498868079
End
Email:***@meditechinsights.com Email Verified
Tags:Decentralized Clinical Trials
Industry:Health
Location:Brussels - Brussels - Belgium
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse



Like PRLog?
9K2K1K
Click to Share